Value of programmed cell death ligand 1 and soluble programmed cell death ligand 1 in predicting the prognosis of hepatocellular carcinoma and related controversies

VernacularTitle:程序性细胞死亡受体1配体及可溶性程序性细胞死亡受体1配体对肝细胞癌预后的预测价值与争议
Author: Guoying FENG ¹ ; Zhengrong SHI ¹
Author Information

1. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Publication Type:Research Article
Keywords: carcinoma, hepatocellular; programmed cell death protein 1; prognosis
From: Journal of Clinical Hepatology 2020;36(8):1858-1861
CountryChina
Language:Chinese
Abstract: At present, there are various treatment methods for hepatocellular carcinoma (HCC), including surgical treatment, interventional treatment, and immunotherapy, and even so, the five-year survival rate of HCC patients is only 12.5%. Influencing factors for the prognosis of HCC have always been the focus of research. With the in-depth research on programmed cell death protein 1 (PD-1) inhibitors in the treatment of HCC in recent years, the role of programmed cell death ligand 1 (PD-L1) and soluble programmed cell death ligand 1 (sPD-L1), as the ligands of PD-1, in immune escape and their value in predicting prognosis have attracted more and more attention. This article elaborates on the current controversies, consensus, and advances in PD-L1 and sPD-L1 as immune markers in evaluating the prognosis of HCC.